DCR-PHXC

DRUG5 trials

Conditions

End Stage Renal DiseaseGenetic DiseaseKidney DiseasesPrimary HyperoxaluriaPrimary Hyperoxaluria Type 1Primary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 2 (PH2)Primary Hyperoxaluria Type 3

Phase 1

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

CompletedNCT03392896

Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyPrimary Hyperoxaluria

Start: 2017-12-06End: 2019-11-19Updated: 2024-09-19

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

CompletedNCT04555486

Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyPrimary Hyperoxaluria Type 3

Start: 2020-09-14End: 2021-09-07Updated: 2024-09-19

Phase 2

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

CompletedNCT03847909

Novo Nordisk A/SGenetic Disease, Kidney Diseases, Primary Hyperoxaluria Type 1 (PH1) +2

Start: 2019-10-28End: 2021-06-29Updated: 2024-05-22

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

RecruitingNCT04580420

Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyEnd Stage Renal Disease, Primary Hyperoxaluria Type 1

Start: 2021-04-15End: 2032-01-30Target: 28Updated: 2025-12-24

Phase 3

Long Term Extension Study in Patients With Primary Hyperoxaluria

Active, not recruitingNCT04042402

Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyGenetic Disease, Kidney Diseases, Primary Hyperoxaluria Type 1 (PH1) +3

Start: 2019-07-09End: 2030-04-01Target: 75Updated: 2025-05-30

Related Papers

Population Pharmacokinetic and Pharmacodynamic Modelling and Simulation for Nedosiran Clinical Development and Dose Guidance in Pediatric Patients with Primary Hyperoxaluria Type 1.

2025-07-02

PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1.

2025-03-251 citations

Nedosiran in pediatric patients with PH1 and relatively preserved kidney function, a phase 2 study (PHYOX8).

2025-01-281 citations